Alfonsi, Chiara
Stephan-Otto, Christian
Cortès-Saladelafont, Elisenda
Palacios, Natalia Juliá
Podzamczer-Valls, Inés
Cruz, Nuria Gutiérrez
Jiménez, María Rosario Domingo
Micó, Salvador Ibáñez
Vila, Miguel Tomás
Jeltsch, Kathrin
Hübschmann, Oya Kuseyri
Opladen, Thomas
Fragua, Ramón Velázquez
Gómez, Teresa
Fortuny, Oscar Alcoverro
Jiménez, Inmaculada García
Laso, Eduardo López
Martínez, Ana Roche
López, Jordi Muchart
Garcia-Cazorla, Àngels http://orcid.org/0000-0001-9853-688X
Funding for this research was provided by:
Instituto de Salud Carlos III (P118/00111)
fondo europeo de desarrollo regional FEDER
Article History
Received: 25 March 2022
Accepted: 29 May 2022
First Online: 4 June 2022
Declarations
:
: The study was approved by the local ethics committee (ID number: PIC-131–18). All the procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013.
: Oral and written informed consent was obtained from all subjects or their parents/legal guardians regarding publishing their data. Images from control subjects were obtained from a local anonymized MRI database, for which the patients or their parents/legal guardians gave informed consent.
: Dr. Cortès-Saladelafont reports personal fees from Takeda, outside the submitted work. Dr. Kuseyri Hübschmann reports personal fees from PTC Therapeutics GT, outside the submitted work. Dr. López-Laso has received honoraria as an invited speaker and has also received consultation fees from PTC Therapeutics, outside the submitted work. Dr. Ibáñez-Micó reports grants and personal fees from PTC Therapeutics, during the conduct of the study. Dr. Alfonsi, Dr. Stephan-Otto, Dr. Juliá Palacios, Dr. Podzamczer-Valls, Dr. Nuria Gutiérrez, Dr. Kathrin Jeltsch, Dr. Velázquez Fragua, Dr. Alcoverro-Fortuny, Dr. Teresa Gómez, Dr. Roche Martínez and Dr. Muchart López have nothing to disclose.